» Articles » PMID: 38459714

Pleural Mesothelioma (PMe): The Evolving Molecular Knowledge of a Rare and Aggressive Cancer

Overview
Journal Mol Oncol
Date 2024 Mar 9
PMID 38459714
Authors
Affiliations
Soon will be listed here.
Abstract

Mesothelioma is a type of late-onset cancer that develops in cells covering the outer surface of organs. Although it can affect the peritoneum, heart, or testicles, it mainly targets the lining of the lungs, making pleural mesothelioma (PMe) the most common and widely studied mesothelioma type. PMe is caused by exposure to fibres of asbestos, which when inhaled leads to inflammation and scarring of the pleura. Despite the ban on asbestos by most Western countries, the incidence of PMe is on the rise, also facilitated by a lack of specific symptomatology and diagnostic methods. Therapeutic options are also limited to mainly palliative care, making this disease untreatable. Here we present an overview of biological aspects underlying PMe by listing genetic and molecular mechanisms behind its onset, aggressive nature, and fast-paced progression. To this end, we report on the role of deubiquitinase BRCA1-associated protein-1 (BAP1), a tumour suppressor gene with a widely acknowledged role in the corrupted signalling and metabolism of PMe. This review aims to enhance our understanding of this devastating malignancy and propel efforts for its investigation.

Citing Articles

Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma.

Luca S, Pignata G, Cioce A, Salzillo C, De Cecio R, Ferrara G Cancers (Basel). 2025; 17(3).

PMID: 39941848 PMC: 11816244. DOI: 10.3390/cancers17030481.


Malignant Mesothelioma: Overcoming Diagnostic Hurdles.

R P, Grace Priyadarshini S, P J Cureus. 2024; 16(9):e68718.

PMID: 39371847 PMC: 11455275. DOI: 10.7759/cureus.68718.


[Advances in Targeted Therapy for Malignant Pleural Mesothelioma].

Fu F, Zhang Y, Shen H Zhongguo Fei Ai Za Zhi. 2024; 27(5):391-398.

PMID: 38880927 PMC: 11183316. DOI: 10.3779/j.issn.1009-3419.2024.102.18.


Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990-2019.

Chen Z, Cai Y, Ou T, Zhou H, Li H, Wang Z J Cancer Res Clin Oncol. 2024; 150(5):282.

PMID: 38806867 PMC: 11133219. DOI: 10.1007/s00432-024-05802-6.

References
1.
Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y . YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis. 2008; 29(11):2139-46. DOI: 10.1093/carcin/bgn200. View

2.
Lee H, Lee S, Hur S, Seo J, Kwon J . Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis. Nat Commun. 2014; 5:5128. DOI: 10.1038/ncomms6128. View

3.
Worthmuller J, Blum W, Pecze L, Salicio V, Schwaller B . Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway. Oncotarget. 2018; 9(91):36256-36272. PMC: 6284738. DOI: 10.18632/oncotarget.26332. View

4.
Pease D, Kratzke R . Oncolytic Viral Therapy for Mesothelioma. Front Oncol. 2017; 7:179. PMC: 5573749. DOI: 10.3389/fonc.2017.00179. View

5.
Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View